February 8th, 2025, Shanghai, China—3D Medicines Inc. (1244.HK) today announced the appointment of Mr. Gan Ding as Chief Commercial Officer (CCO). With three decades of experience in the biopharmaceutical industry across China, the United States, and internationally, Mr. Ding brings a wealth of expertise that will drive the future commercial development of 3D Medicines.

Mr. Ding has extensive experience in pipeline planning, R&D project support, clinical development strategies, pre-market commercialization preparation, post-market expansion, and lifecycle management of products post-patent expiration. Early in his career, he worked at the global headquarters and U.S. divisions of Eli Lilly and GlaxoSmithKline, deeply involved in oncology pipeline planning, project decision support, brand market strategy and management, new product development, and global and U.S. market pricing and channel strategies. He led the launch of a radiotherapy immunotherapy product in the U.S. and headed a global commercial strategy team to develop global launch plans and commercialization strategies for the company's core oncology pipeline products.

In 2008, Mr. Ding returned to China, where he managed commercial operations, led the development of new prescription drugs and central marketing at GlaxoSmithKline China, and established and managed the emerging markets community health division. He also founded the first contract clinical service promotion division (CSO) for Cardinal Health, a global healthcare distribution giant. In 2017, Mr. Ding became the General Manager of Mylan Pharmaceuticals China, one of the world's top three generic drug companies, overseeing commercial operations and the implementation of future China strategies. From 2021 to 2024, Mr. Ding served as CEO of two biopharmaceutical startups, one focused on chronic diseases, where he quickly built R&D and operational teams and established a comprehensive product pipeline within ten months through both in-licensing and in-house development. In addition to his roles in multinational companies, Mr. Ding has also worked as an independent business and consulting advisor, providing overseas M&A and market expansion strategy consulting services to PE firms and several large pharmaceutical companies. During this time, he served as a part-time Senior Director in the management consulting department of IQVIA.

Dr. Zhaolong Gong, Chairman and CEO of 3D Medicines, stated, "We are delighted to welcome Mr. Gan Ding to our team. His extensive experience and exceptional leadership in the biopharmaceutical field will bring tremendous value to the future development of 3D Medicines."

Mr. Ding commented, "I am honored to join 3D Medicines and look forward to working with the team to drive the company's growth. I believe that with our team's efforts and innovative spirit, 3D Medicines will achieve greater success in the biopharmaceutical field."

Mr. Ding graduated from the Department of Chemistry at Peking University with a Bachelor of Science degree and later taught at Tongji University in Shanghai. In 1988, he went to the United States to study and obtained a Master's degree in Bioanalytical Chemistry from Rutgers University. He also holds an MBA from the Stern School of Business at New York University.

3D Medicines is committed to developing oncology drugs with differentiated clinical value. The company has multiple innovative drugs in clinical development and one successfully commercialized innovative drug product, aiming to provide patients with more and better clinical options.